{"product_id":"addiction-medicine-for-non-specialists","title":"Oakstone Addiction Medicine for Non-Specialists 2022","description":"\u003cem\u003eOakstone Addiction Medicine for Non-Specialists 2022 Addiction Medicine for Non-Specialists\u003c\/em\u003e is a case-based CME course designed to guide non-specialists in recognition, evaluation, treatment, and follow-up of patients with substance use disorders.\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e Include: 20 videos + 2 pdfs, size: 3.53 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: internists, family physicians, general psychiatrists, emergency physicians, adolescent medicine doctors, pediatricians, and general neurologists\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3\u003eExplore Substance Use Disorder Topics with Online CME\u003c\/h3\u003e\n\u003cem\u003eAddiction Medicine for Non-Specialists\u003c\/em\u003e is a case-based CME course designed to guide non-specialists in recognition, evaluation, treatment, and follow-up of patients with substance use disorders. Led by Antoine Douaihy, MD, experienced practitioners cover substances used — alcohol, opioids, stimulants, benzodiazepines, tobacco\/nicotine, cannabis — and outline how the non-specialist can help their patient stop using drugs, maintain a drug-free lifestyle, and function in family and in society. Treatment strategies discussed include pharmacological, cognitive-behavioral, and a combination of the two.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eGood to Know:\u003c\/strong\u003e This activity meets the Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) requirement that as of June 27, 2023, new or renewing DEA registrants must complete a minimum of 8 hours of accredited continuing education (CE) on the treatment and management of patients with opioid or other substance use disorders before renewing their license.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eDate of Original Release:\u003c\/strong\u003e December 31, 2022\u003cbr\u003e\u003cstrong\u003eDate Credits Expire:\u003c\/strong\u003e December 31, 2025\u003cbr\u003e\u003cstrong\u003eEstimated Time to Complete:\u003c\/strong\u003e 14.25 hours\u003cbr\u003e\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\n\u003cem\u003eAt the completion of this course, you should be able to:\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDiscuss integrated treatment of co-occurring substance use disorder and psychiatric illness\u003c\/li\u003e\n\u003cli\u003eList adverse consequences faced by patients’ long-term opioid therapy and serious illness\u003c\/li\u003e\n\u003cli\u003eExplain the caveats in treating pregnant women with substance use disorder\u003c\/li\u003e\n\u003cli\u003eCompare treatment strategies for opioid use disorder and stimulant use disorder\u003c\/li\u003e\n\u003cli\u003eList the principles of motivational interviewing in the context of substance use disorders\u003c\/li\u003e\n\u003cli\u003eCompare inherent dilemmas in treating chronic pain and acute pain and substance use disorder\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eIntended Audience\u003c\/h3\u003e\u003cbr\u003eThis educational activity was designed for internists, family physicians, general psychiatrists, emergency physicians, adolescent medicine doctors, pediatricians, and general neurologists.\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp style=\"padding-left: 40px;\"\u003e1. Addiction – An Overview – Antoine Douaihy, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e2. Neurobiological Aspects of Substance Use Disorder – Jody Glance, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e3. Screening, Evaluation, and Diagnosis of Substance Use Disorders – Daniel Cohen, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e4. Management of Intoxication, Withdrawal, and Perioperative Care in Individuals Using Substances – Tiffany Reid, PharmD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e5. Alcohol Use Disorder – Antoine Douaihy, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e6. Stimulant Use Disorder – James R. Latronica, DO, FASAM.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e7. Opioid Use Disorder – Julie Kmiec, DO.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e8. Sedative, Hypnotic, and Anxiolytic (Benzodiazepine) Use Disorder – Tae Woo Park, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e9. Cannabis Use Disorder – Thersilla Oberbarnscheidt, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e10. Tobacco Use Disorder – Melanie Yabs, PharmD, BCPP.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e11. Treating Chronic Pain and Substance Use Disorder – Mark Ilgen, PhD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e12. Acute Pain and Substance Use Disorder – Julie Wilson Childers, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e13. Brief Interventions for Substance Use Disorders – Cassandra Boness, PhD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e14. The Treatment of Patients with Substance Use Disorders and Co-occurring Psychiatric Illness – Roger D. Weiss, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e15. Harm Reduction Strategies – Janice Pringle, PhD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e16. Women and Pregnancy – Jody Glance, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e17. Medication Assisted Treatment for Adolescent Substance Use Disorder – Marla Kushner, DO.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e18. Healthcare and Racial Disparities in Addiction Treatment – Antoine Douaihy, MD.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e19. Chronic Pain and Long-term Opioid Therapy – Evidence-based Management – Jessica S. Merlin, MD, PhD, MBA.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e20. Pain and Opioid Complexity in Individuals with Serious Illness – Jessica S. Merlin, MD, PhD, MBA.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003eQuestions.pdf\u003cbr\u003eSyllabus.pdf\u003c\/p\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954375954530,"sku":"MED-AMB02186","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Oakstone-Addiction-Medicine-for-Non-Specialists-2022.jpg?v=1779374886","url":"https:\/\/meducourse.com\/products\/addiction-medicine-for-non-specialists","provider":"Meducourse","version":"1.0","type":"link"}